The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study

Gabor Liposits; Jesper Ryg; Stine Braendegaard Winther; H. Skuladottir; Sören Möller; Eva Hofsli; C Shah; L. Poulsen; Ida Berglund; C. Qvortrup; Pia Osterlund; Bengt Glimelius; Halfdan Sorbye; Per Pfeiffer

doi:10.1016/j.annonc.2023.04.505

The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study

Gabor Liposits, Jesper Ryg, Stine Braendegaard Winther, H. Skuladottir, Sören Möller, Eva Hofsli, C Shah, L. Poulsen, Ida Berglund, C. Qvortrup, Pia Osterlund, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

24 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	SO-33
Tidsskrift	Annals of Oncology
Vol/bind	34
Udgave nummer	Suppl. 1
Sider (fra-til)	176-177
ISSN	0923-7534
DOI	https://doi.org/10.1016/j.annonc.2023.04.505
Status	Udgivet - 27. jun. 2023
Begivenhed	Wold Congress on Gastrointestinal Cancer 2023: ESMO GI - Barcelona Varighed: 28. jun. 2023 → 1. aug. 2023

Konference

Konference	Wold Congress on Gastrointestinal Cancer 2023
By	Barcelona
Periode	28/06/2023 → 01/08/2023

Dokumenter og links

10.1016/j.annonc.2023.04.505

NORDIC9_ESMOGI_2023Forlagets udgivne version, 110 KBLicens: Ikke-specificeret

Citationsformater

Liposits, G., Ryg, J., Winther, S. B., Skuladottir, H., Möller, S., Hofsli, E., Shah, C., Poulsen, L., Berglund, I., Qvortrup, C., Osterlund, P., Glimelius, B., Sorbye, H., & Pfeiffer, P. (2023). The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study. Annals of Oncology, 34(Suppl. 1), 176-177. Artikel SO-33. https://doi.org/10.1016/j.annonc.2023.04.505

@article{777b2903ec8d454694fa8994eb98f042,

title = "The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study",

author = "Gabor Liposits and Jesper Ryg and Winther, {Stine Braendegaard} and H. Skuladottir and S{\"o}ren M{\"o}ller and Eva Hofsli and C Shah and L. Poulsen and Ida Berglund and C. Qvortrup and Pia Osterlund and Bengt Glimelius and Halfdan Sorbye and Per Pfeiffer",

year = "2023",

month = jun,

day = "27",

doi = "10.1016/j.annonc.2023.04.505",

language = "English",

volume = "34",

pages = "176--177",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 1",

note = "Wold Congress on Gastrointestinal Cancer 2023 : ESMO GI, WCGIC 2023 ; Conference date: 28-06-2023 Through 01-08-2023",

}

Liposits, G, Ryg, J, Winther, SB, Skuladottir, H, Möller, S, Hofsli, E, Shah, C, Poulsen, L, Berglund, I, Qvortrup, C, Osterlund, P, Glimelius, B, Sorbye, H & Pfeiffer, P 2023, 'The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study', Annals of Oncology, bind 34, nr. Suppl. 1, SO-33, s. 176-177. https://doi.org/10.1016/j.annonc.2023.04.505

The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study. / Liposits, Gabor; Ryg, Jesper; Winther, Stine Braendegaard et al.
I: Annals of Oncology, Bind 34, Nr. Suppl. 1, SO-33, 27.06.2023, s. 176-177.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study

AU - Liposits, Gabor

AU - Ryg, Jesper

AU - Winther, Stine Braendegaard

AU - Skuladottir, H.

AU - Möller, Sören

AU - Hofsli, Eva

AU - Shah, C

AU - Poulsen, L.

AU - Berglund, Ida

AU - Qvortrup, C.

AU - Osterlund, Pia

AU - Glimelius, Bengt

AU - Sorbye, Halfdan

AU - Pfeiffer, Per

PY - 2023/6/27

Y1 - 2023/6/27

U2 - 10.1016/j.annonc.2023.04.505

DO - 10.1016/j.annonc.2023.04.505

M3 - Conference abstract in journal

SN - 0923-7534

VL - 34

SP - 176

EP - 177

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 1

M1 - SO-33

T2 - Wold Congress on Gastrointestinal Cancer 2023

Y2 - 28 June 2023 through 1 August 2023

ER -

Liposits G, Ryg J, Winther SB, Skuladottir H, Möller S, Hofsli E et al. The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - a post-hoc exploratory analysis of the randomized NORDIC9-study. Annals of Oncology. 2023 jun. 27;34(Suppl. 1):176-177. SO-33. doi: 10.1016/j.annonc.2023.04.505